SM-15178
SM-15178 is a potent, orally active and selective leukotriene B4 (LTB4) receptor antagonist with an IC50 of 0.30 μM. SM-15178 attenuates LTB4 (HY-107608)-induced neutrophil accumulation in mouse skin and bronchoconstriction in guinea pigs. SM-15178 emonstrates significant anti-inflammatory efficacy across multiple animal models of inflammation. SM-15178 can be used for the research of chronic inflammatory diseases such as inflammatory bowel disease, psoriasis, and asthma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 146461-98-5
- Formule: C22H26N2O6
- Masse moléculaire:414.46
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform Leukotriene Receptor
More
Activité biologique
|
LTB4 0.30 μM (IC50) |
SM-15178 (30 min) inhibits LTB4 binding to human neutrophils in a dose-dependent manner (IC50 = 0.30 μM)[3].
SM-15178 (up to 30 μM; 15-90 min) inhibits LTB4-induced chemotaxis of mouse and rat neutrophils and guinea pig eosinophils (IC50 = 0.52-0.72 μM)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
SM-15178 (5 mg/kg; i.v.; 2-30 min pre-LTB4, or 40 mg/kg; p.o.; 60 min pre-LTB4) potently inhibits LTB4-induced bronchoconstriction in guinea pigs[2].
SM-15178 (20-40 mg/kg; p.o.; single dose) suppresses LTB4-induced transient leukopenia in guinea pigs[3].
SM-15178 (5-100 mg/kg; p.o.; single dose) suppresses Arachidonic Acid-induced neutrophil infiltration in mice[3].
SM-15178 (10-100 mg/kg; p.o.; one day or 1 h before SRBC challenge) inhibits sheep red blood cells (SRBC)-induced paw edema in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6N mice induced by LTB4[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; single dose
-
Result:Significantly reduced LTB4-induced neutrophil accumulation by 70.3%.
-
Animal Model:Guinea pigs challenged with LTB₄[2]
-
Dosage:5 mg/kg (i.v.); 40 mg/kg (p.o.)
-
Administration:i.v.; 2, 10, or 30 min pre-LTB₄; p.o.; 60 min pre-LTB₄
-
Result:Showed potent inhibitory activity against LTB₄-induced bronchoconstriction at all dosages.
-
Animal Model:Male Hartley Guinea pigs (400-450 g) intravenously injected with LTB₄[3]
-
Dosage:20, 40 mg/kg
-
Administration:p.o.; single dose; 1 h pre-LTB4
-
Result:Significantly suppressed LTB₄-induced transient leukopenia and LTB₄-induced bronchoconstriction.
-
Animal Model:Male BALB/c (20-30 g) topically applied with Arachidonic Acid[3]
-
Dosage:5, 25, 50, 100 mg/kg
-
Administration:p.o.; single dose
-
Result:Suppressed arachidonic acid-induced increases in myeloperoxidase (MPO) levels in a dose-dependent manner.
-
Animal Model:Male BALB/c (25-30 g) injected with SRBC[3]
-
Dosage:10, 25, 50, 100 mg/kg
-
Administration:p.o.; one day or 1 hour before SRBC
-
Result:Inhibited Arthus reaction-induced paw edema in a dose-dependent manner with a minimum effective dose of 25 mg/kg.
Chemical Information
-
CAS No. 146461-98-5
-
Masse moléculaire 414.46
-
Formule C22H26N2O6
-
SMILES
O=C(O)CCN(C(=O)C=1N=C(C=CC1)COC2=CC(O)=C(C=C2CC)C(=O)C)CC
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Ohnishi M, et al. Role of P-selectin in the migration of neutrophils to chemoattractant-induced cutaneous inflammation in mice. Inflammation. 2000;24(6):583-593. [Content Brief]
[3]. Ohmi N, et al. Pharmacological profile of a novel, orally active leukotriene B4 antagonist, SM-15178. Inflammation. 1994;18(2):129-140. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)